Introduction: When to Seek Diagnostic Testing

People who should undergo diagnostic testing for lung squamous cell carcinoma include those experiencing persistent symptoms that might indicate lung problems. The most common symptom that brings patients to doctors is a cough that won’t go away, which is reported as the most common sign of lung cancer.^[8] Other warning signs include weight loss without trying to lose it, shortness of breath or wheezing sounds when breathing, chest pain, coughing up blood or rust-colored spit, and a hoarse voice that doesn’t improve.^[8]

Stage 3 lung cancer symptoms appear because the disease has progressed beyond the early stages when it might not cause any noticeable problems. This is partly why the disease often worsens quickly and doesn’t have clear signs in the beginning stages.^[8] If the cancer has spread to areas beyond the lungs, additional symptoms might appear depending on which body parts are affected. For instance, if cancer reaches the bones, patients may experience bone pain.^[8]

It’s important to understand that most people aren’t routinely checked for lung cancer unless they smoke or face other higher risks.^[8] This means that if you notice any of these symptoms, especially if they persist for weeks, you should talk to your doctor about getting tested. Early detection through proper diagnostic testing can significantly impact treatment options and outcomes.

Classic Diagnostic Methods for Identifying Lung Squamous Cell Carcinoma

Initial Imaging Tests

When a doctor suspects lung cancer based on your symptoms, the diagnostic journey typically begins with a chest X-ray. This is often the first imaging test ordered because it can quickly reveal abnormalities in the lungs.^[8] A chest X-ray uses radiation to create pictures of the inside of your body, and different body structures absorb the X-ray beam differently to create the image.^[25] If the X-ray suggests that cancer might be present, your doctor will order additional, more detailed tests to learn more about what’s happening inside your chest.

Following an initial chest X-ray that raises concerns, doctors typically order a CT scan, which stands for computed tomography scan. This test is frequently used to evaluate squamous cell carcinoma of the lung, provided the tumor is large enough to be detected on the scan.^[12] A CT scan creates a three-dimensional image of your body by using a machine that moves around you, taking multiple pictures from different angles.^[3] Your doctor may order a special type called a “contrast-enhanced” CT scan, which uses a special dye to make certain areas show up more clearly in the images.^[8]

Advanced Imaging Procedures

Beyond basic X-rays and CT scans, doctors may use several other imaging technologies to get a complete picture of the cancer. MRI scans, which stands for magnetic resonance imaging, use magnets, radio waves, and a computer to create detailed images of your body’s soft tissues.^[3] These scans are particularly helpful for looking at how cancer might have spread to certain organs or tissues.

PET scans, or positron emission tomography scans, are imaging tests used to diagnose certain diseases and see how far they have spread in the body.^[3] These scans can help doctors understand whether cancer has traveled to lymph nodes or other parts of the body. Sometimes doctors combine different types of scans to get the most complete information possible about the cancer’s location and extent.

Tissue Sampling and Biopsy

While imaging tests can show suspicious areas, the only way to definitively confirm lung cancer is through a biopsy. A biopsy involves taking a small sample of tissue from the suspicious area and examining it under a microscope to look for cancer cells.^[16] If lung cancer is suspected based on imaging results, doctors will perform a biopsy to confirm the diagnosis.^[16]

There are different ways to obtain tissue samples from the lungs. One common method is bronchoscopy, where doctors insert a thin, flexible tube with a camera through your nose or mouth and down into your airways to look at the lungs and take tissue samples. Another approach might involve inserting a needle through the chest wall to reach the tumor, guided by CT scan images to ensure accuracy. The specific method chosen depends on where the tumor is located and other factors related to your individual situation.

Laboratory Analysis of Samples

Once tissue samples are obtained, they undergo detailed laboratory examination. Doctors look at the cancer cells under a microscope to determine what type of lung cancer is present. The cancer cells of each type look different under a microscope and are named for the kinds of cells found in the cancer.^[16] Squamous cell carcinoma is a type of lung cancer that forms in the thin, flat cells lining the inside of the lungs, also called epidermoid carcinoma.^[16]

Laboratory tests also help determine whether the cancer is non-small cell lung cancer or small cell lung cancer, which are the two main categories. These two types look different under the microscope and are treated differently.^[9] Non-small cell lung cancer, which includes squamous cell carcinoma, tends to have a better outlook than small cell lung cancer because it’s more likely to be contained in one area, making treatment more likely to be successful.^[9]

Staging Procedures

After lung cancer has been diagnosed, doctors perform additional tests to determine if cancer cells have spread within the chest or to other parts of the body.^[16] This process is called staging, and it helps doctors understand exactly how advanced the cancer is. Staging uses three key criteria called TNM: Tumor (how big and where is it?), Nodes (is the cancer in nearby lymph nodes?), and Metastasis (how far has it spread from its original spot?).^[8]

For stage 3 lung cancer specifically, doctors need to determine whether it’s stage 3A, 3B, or 3C, as each substage has different characteristics and treatment approaches. Stage 3A means the cancer is in one lung and has spread to nearby lymph nodes on the same side of the chest. Stage 3B indicates the cancer may have spread to lymph nodes above the collarbone or on the opposite side of the chest. Stage 3C is the most advanced within stage 3, where cancer has spread to lymph nodes on the opposite side or above the collarbone, and may be in the chest wall, heart, breastbone, and other nearby tissues, but hasn’t spread to distant organs.^[8]

To complete staging, doctors may perform additional procedures such as mediastinoscopy, where they examine and take samples from lymph nodes in the area between the lungs. They might also test fluids around the lungs or check other organs to ensure cancer hasn’t spread to distant locations. All of this information together helps create a complete picture of the disease stage.

Diagnostic Tests for Clinical Trial Qualification

Standard Qualification Criteria

When patients with stage III lung squamous cell carcinoma consider participating in clinical trials, they must undergo specific diagnostic tests that serve as standard criteria for enrollment. Clinical trials have strict requirements to ensure that participants are appropriate for the experimental treatments being tested and that results can be accurately measured and compared.

One essential component of trial qualification is confirming the exact stage and extent of the disease through comprehensive imaging. This typically includes detailed CT scans of the chest and often the abdomen to assess tumor size, location, and spread to lymph nodes or nearby structures. The staging must be confirmed using the TNM system, which categorizes the tumor, node involvement, and metastasis status. For stage III disease, this means confirming that cancer is locally advanced but has not spread to distant organs.^[14]

Biomarker and Molecular Testing

Modern clinical trials for lung cancer increasingly require biomarker testing, which involves analyzing the tumor for specific genetic changes or proteins. Biomarkers are biological characteristics that can help determine which treatments might work best for individual patients. During the diagnostic process, doctors perform cell and tissue studies to look for specific genetic mutations.^[11]

For non-small cell lung cancer, including squamous cell carcinoma, one important test looks for changes in the EGFR gene, which stands for epidermal growth factor receptor. EGFR is a receptor on the surface of cells that sends signals allowing them to grow and divide. A mutation in this gene can cause cancer cells to grow and divide more than they should.^[11] The type of treatment available, including enrollment in certain clinical trials, depends on whether these specific mutations are found during diagnostic testing.

Clinical trials may also require testing for other molecular markers or genetic characteristics that predict how the cancer might respond to specific experimental therapies. These tests are performed on the tissue samples obtained during the initial biopsy and help researchers match patients to trials where they’re most likely to benefit from the investigational treatment.

Functional Status Assessment

Beyond imaging and laboratory tests, clinical trial enrollment typically requires assessment of a patient’s overall health and ability to tolerate treatment. This includes evaluating how well vital organs function, particularly the heart, kidneys, and liver. Doctors perform blood tests to check organ function and ensure that patients are healthy enough to participate safely in trials.

Lung function is especially important for patients with lung cancer. Doctors may perform pulmonary function tests that measure how well the lungs work, including how much air the lungs can hold and how quickly air can move in and out. These tests help determine whether patients can safely undergo certain treatments without experiencing severe breathing problems.

Clinical trials also assess patients’ general health using standardized scales that measure their ability to perform daily activities. This helps researchers understand whether patients are strong enough to handle potentially intensive experimental treatments and complete the full course of study participation. Only patients who meet minimum health criteria are enrolled to ensure both safety and the ability to evaluate treatment effectiveness accurately.